



BC Centre for Disease Control
Provincial Health Services Authority

Communicable Diseases and Immunization Service
655 West 12th Avenue
Vancouver, BC V5Z 4R4

Tel 604.707.2548
Fax 604.707.2515
www.bccdc.ca

Date: April 26, 2022

Administrative Circular: 2022:16

ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

**Re: Update to Communicable Disease Control Manual, Chapter 2: Immunization,
Part 4 – Biological Products**

Part 4 – Biological Products

COVID-19 Vaccines

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Adult/Adolescent)

- **Doses and Schedule:**
Footnote C has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.
- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

Please remove page numbers: 1-7 dated April 13, 2022
Please add new page numbers: 1-6 dated April 26, 2022

COVID-19 Vaccine COMIRNATY® (Pfizer-BioNTech) (Pediatric)

- **Doses and Schedule:**
Footnote C has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.
- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

Please remove page numbers: 1-6 dated March 18, 2022
Please add new page numbers: 1-5 dated April 26, 2022

Page 1 of 3

COVID-19 Vaccine SPIKEVAX™ (Moderna)

- **Doses and Schedule:**

Footnote B has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

Please remove page numbers: 1-6 dated April 13, 2022

Please add new page numbers: 1-5 dated April 26, 2022

COVID-19 Vaccine VAXZEVRIA™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals)

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

Please remove page numbers: 1-5 dated April 13, 2022

Please add new page numbers: 1-4 dated April 26, 2022

COVID-19 Vaccine (Ad26.COV2.S [recombinant]) (Janssen Inc.)

- The ADDENDUM: Pooling residual vaccine from up to three vials to constitute an extra dose has been removed. While this was an appropriate strategy at the implementation of the COVID-19 vaccination program, vaccine supply is no longer an issue and it is a deviation from best practice.

Please remove page numbers: 1-5 dated April 13, 2022

Please add new page numbers: 1-4 dated April 26, 2022

COVID-19 Vaccine Nuvaxovid™ (Novavax)

- **Doses and Schedule:**

Footnote C has been revised to indicate clients requesting a shorter interval between doses should be informed that this is not optimal for protection, but their request for an earlier dose should be granted, without need for MHO approval.

Please remove page numbers: 1-3 dated April 13, 2022

Please add new page numbers: 1-3 dated April 26, 2022

If you have any questions or concerns, please contact Stephanie Meier, Senior Practice Leader, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,



Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:

Provincial Health Officer
Dr. Bonnie Henry

Dr. Reka Gustafson
Vice President, Public Health &
Wellness, PHSA & Deputy Provincial
Health Officer

Deputy Provincial Health Officer
Dr. Martin Lavoie

BC Ministry of Health, Population &
Public Health Division:

Brian Sagar
Senior Director Communicable
Disease, Population and Public Health
Division

Bernard Achampong
Executive Director,
Public Health, Planning and Prevention,
Population and Public Health Division